Richard E. Uihlein - 26 Jan 2023 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role: Director, 10%+ Owner
Signature: Jack W. Callicutt, by power of attorney
Issuer symbol: GALT
Transactions as of: 26 Jan 2023
Net transactions value: +$40,000
Form type: 4
Filing time: 30 Jan 2023, 15:34:17 UTC
Previous filing: 08 Feb 2022
Next filing: 27 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GALT	Common Stock	Award	$40,000	+36,036	+0.45%	$1.11	7,999,291	26 Jan 2023	Direct	F1
holding	GALT	Common Stock						27,710	26 Jan 2023	By Ed Uihlein Family Foundation	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GALT	Stock Option (right to buy)	Award	$0	+40,000		$0.000000	40,000	26 Jan 2023	Common Stock	40,000	$1.11	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2023. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2023.
F2	The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
F3	The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F4	The options vest 100% on December 31, 2023.